ALM223
/ Almirall, Simcere
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
November 10, 2025
Simcere Pharmaceutical Group…announced that its regulatory T cells(Treg)-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in China for the treatment of moderate-to-severe atopic dermatitis (AD)
(PRNewswire)
- "The first dose was achieved in Hangzhou First People's Hospital. This randomized, double-blind, placebo-controlled, multi-center Phase II study is aiming to evaluate the efficacy, safety, and pharmacokinetics of continuous subcutaneous administration of SIM0278 in participants with moderate-to-severe AD."
Trial status • Atopic Dermatitis
September 12, 2025
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects
(clinicaltrials.gov)
- P1 | N=60 | Completed | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting ➔ Completed
Trial completion
September 17, 2025
A Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
(clinicaltrials.gov)
- P2 | N=184 | Not yet recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
New P2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology
April 10, 2024
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects
(clinicaltrials.gov)
- P1 | N=84 | Recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. | Trial completion date: Dec 2024 ➔ Jul 2025 | Trial primary completion date: Sep 2024 ➔ May 2025
Trial completion date • Trial primary completion date • CD4 • CD8
September 01, 2023
To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SIM0278 in Chinese Healthy Subjects
(clinicaltrials.gov)
- P1 | N=84 | Recruiting | Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
New P1 trial
1 to 5
Of
5
Go to page
1